Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 601–700 of 1,004
Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 54
A Comprehensive Review on Postmenopausal Osteoporosis in Women
Charde, S. H., Joshi, A., & Raut, J. M. (2023) · Cureus · doi:10.7759/cureus.48582 · Cited by 93
Treatment of primary osteoporosis in men
Bianchi, G., & Giusti, A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s44057 · Cited by 63
Health Technology Assessment in Osteoporosis
Hiligsmann, M., Kanis, J. А., Compston, J. E., Cooper, C. C., Flamion, B., Bergmann, P., Body, J., Boonen, S., Bruyère, O., Devogelaer, J., et al. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9724-8 · Cited by 49
“doxifene [38], denosumab [39], ibandronate [40], strontium ranelate [41], and zoledronic acid [42].”
Self-citationDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Raje, N. S., & Yee (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s14566 · Cited by 62
“Clinical Interventions in Aging 2012:7 of bisphosphonates in the treatment of osteoporosis with daily oral alendronate (FIT),(10) daily oral risedronate (VERT),(11) and intravenous bisphosphonate zoledronic acid given yearly (HORIZON).(12) In addition to its role in treating osteoporosis, zoledronic acid has played a…”
BackgroundKoivisto, K., Kyllönen, E., Haapea, M., Niinimäki, J. L., Sundqvist, K., Pehkonen, T., Seitsalo, S., Tervonen, O. A., & Karppinen, J. I. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-64 · Cited by 51
Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature
Kreutle, V., Blum, C. A., Meier, C., Past, M., Müller-Stich, B. P., Schüetz, P., & Borm, K. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13979 · Cited by 49
Li, C., Wang, H., Li, X., Zhou, X., & Dong, J. (2012) · Acta Neurochirurgica · doi:10.1007/s00701-012-1283-7 · Cited by 49
“For the treatment of osteoporosis, the recommended dose of ZOL is 5 mg [2, 18].”
BackgroundBhuriya, R., Singh, M., Molnár, J., Arora, R. R., & Khosla, S. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.11.041 · Cited by 49
Osteoporosis treatment: a missed opportunity
Milat, F., & Ebeling, P. R. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00568 · Cited by 56
Malouf, J., Tarantino, U., García-Hernández, P. A., Corradini, C., Overgaard, S., Stepan, J. J., Borris, L. C., Lespessailles, É., Frihagen, F., Papavasiliou, K., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3067 · Cited by 52
“5% at 12 and 24 months, respectively).((58))”
Chen, J., Hsu, C., Yu, S., Ko, C., Chiu, W.-C., Lai, H., Chen, Y., Su, Y., & Cheng, T. (2020) · Rheumatology · doi:10.1093/rheumatology/kez655 · Cited by 56
Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations
Pοlyzos, S. A., Anastasilakis, A. D., Efstathiadou, Z. A., Yavropoulou, M. P., & Makras, P. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.02.007 · Cited by 53
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., & Haentjens, P. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02010.x · Cited by 55
Self-citationDiabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk
Eastell, R., Vittinghoff, E., Lui, L., Ewing, S. K., Schwartz, A. V., Bauer, D. C., Black, D. M., & Bouxsein, M. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4697 · Cited by 53
“(3) Nonetheless, it should be remembered that the participants enrolled in these trials, both with and without diabetes, are not representative of the (Figure legend continued from previous page.) e. Change in PINP FIT I (alendronate) FIT II (alendronate) HIP (risendronate) HORIZON PFT (zoledronic acid intravenous) Al…”
BackgroundSelf-citationMou, K., Chan, S. M. H., & Vlahos, R. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108635 · Cited by 59
Assaf, A. T., Smeets, R., Riecke, B., Weise, E., Gröbe, A., Blessmann, M., Steiner, T., Wikner, J., Friedrich, R. E., Heiland, M., et al. (2013) · PubMed · Cited by 48
Adverse drug reactions to osteoporosis treatments
Rizzoli, R., & Reginster, J. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.42 · Cited by 52
Wilkes, M. M., Navickis, R. J., Chan, W. W., & Lewiecki, E. M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0991-1 · Cited by 51
“[2] 7,765 North and South America, Europe, Australia, Asia 3 Zoledronic acid Yearly; 5 mg i.”
BackgroundClinical and therapeutic aspects of osteoporosis
Compston, J. E. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.04.063 · Cited by 57
“PTH[1–84]”
BackgroundZoledronic Acid in Osteoporosis Secondary to Mastocytosis
Rossini, M., Zanotti, R., Viapiana, O., Tripi, G., Idolazzi, L., Biondan, M., Orsolini, G., Bonadonna, P., Adami, S., & Gatti, D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.06.015 · Cited by 51
NOFSA Guideline for the Diagnosis and Management of Osteoporosis
Hough, S. F., Ascott-Evans, B. H., Brown, S. L., Cassim, B., de Villiers, T. J., Lipschitz, S., Pettifor, J. M., & Sonnendecker, E. W. W. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872239 · Cited by 56
Osteoporosis: the emperor has no clothes
Järvinen, T. L. N., Michaëlsson, K., Aspenberg, P., & Sievänen, H. T. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12366 · Cited by 56
Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis
Songpatanasilp, T., Sritara, C., Kitisomprayoonkul, W., Chaiumnuay, S., Nimitphong, H., Charatcharoenwitthaya, N., Pongchaiyakul, C., Namwongphrom, S., Kitumnuaypong, T., Srikam, W., et al. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.10.002 · Cited by 61
“- Once a year Zoledronic acid intravenous injection can increase bone density of vertebra, reduce risk of fracture at vertebra, hip and other bone in postmenopausal women [98,99] and men with osteoporosis and reduce mortality rates in patients with operable hip fracture [100].”
BackgroundA Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma
Howie, R. N., Borke, J. L., Kurago, Z., Daoudi, A., Cray, J., Zakhary, I., Brown, T. L., Raley, J. N., Tran, L. T., Messer, R. L. W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132520 · Cited by 47
“[8] Cancer patients receive an intravenous infusion of 4mg of zoledronate over 15 minutes every 3–4 weeks.[12,13] The overall prevalence of BRONJ with zoledronate is around 7.”
BackgroundTadrous, M., Wong, L., Mamdani, M., Juurlink, D. N., Krahn, M. D., Lévesque, L. E., & Cadarette, S. M. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2576-2 · Cited by 49
“hypothesize that this difference may, in large part, be due to the higher incidence of nausea caused by the annual IV infusion of zoledronic acid [4, 7, 29].”
BackgroundRecovery From SIADH-Associated Osteoporosis: A Case Report
Sejling, A., Thorsteinsson, A., Pedersen‐Bjergaard, U., & Eiken, P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1572 · Cited by 51
“Similar results have been obtained in women (17).”
ResultTrial, F. T. H. P. F., Eastell, R., Lang, T., Boonen, S., Cummings, S. R., Delmas, P. D., Cauley, J. A., Horowitz, Z. D., Kerzberg, E. M., Bianchi, G., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1077-9 · Cited by 47
“In a 3-year study, zoledronic acid reduced the risk of vertebral fracture by 70% and the risk of hip fracture by 41% compared with placebo persistently over 3 years [1].”
BackgroundMethodResultInfluentialSelf-citationEffectiveness of bisphosphonate therapy in a community setting
Feldstein, A. C., Weycker, D. A., Nichols, G. A., Oster, G., Rosales, G. A., Boardman, D. L., & Perrin, N. (2008) · Bone · doi:10.1016/j.bone.2008.09.006 · Cited by 48
“Second, prior bisphosphonate studies revealed a greater treatment effect on the incidence of vertebral, hip, and wrist fractures when compared to any clinical fracture [5,6,8,31,32].”
The Effect of Zoledronic Acid on the Volume of the Fusion-Mass in Lumbar Spinal Fusion
Park, Y., Kim, H.-S., Baek, S.-W., Kong, D.-Y., & Ryu, J. A. (2013) · Clinics in Orthopedic Surgery · doi:10.4055/cios.2013.5.4.292 · Cited by 46
Cooper, C. C., Reginster, J., Cortet, B., Díaz Curiel, M., Lorenc, R. S., Kanis, J. А., & Rizzoli, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.663750 · Cited by 55
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Clarke, B. L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79098-x · Cited by 47
Robinson, L., Aldridge, V. K., Clark, E., Misra, M., & Micali, N. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.05.011 · Cited by 53
“Five studies reported significant increases in BMI in participants following the study intervention [32,35,45,46,48], with the remaining studies reporting non-significant differences or failing to disclose a change in BMI.”
BackgroundInfluentialGrey, A. B., Bolland, M. J., Horne, A. M., Mihov, B., Gamble, G. D., & Reid, I. R. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.161207 · Cited by 46
Self-citationModeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
Dempster, D. W., Chines, A. A., Bostrom, M. P., Nieves, J. W., Zhou, H., Chen, L., Pannacciulli, N., Wagman, R. B., & Cosman, F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4006 · Cited by 48
Self-citationPlain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today?
Ringe, J. D. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00842-0 · Cited by 52
Cancer Treatment-Related Bone Disease
Brown, S. A., & Guise, T. A. (2009) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i1.20 · Cited by 49
“Reductions in vertebral and hip fractures have been reported in healthy postmenopausal women receiving oral alendronate, oral risedronate and intravenous zoledronic acid.(76-78) Oral clodronate and oral ibandronate has reduced vertebral fractures in healthy postmenopausal women.”
BackgroundJansen, J. P., Bergman, G. J. D., Huels, J., & Olson, M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903035281 · Cited by 47
“1862 Efficacy of bisphosphonates in osteoporosis 2009 Informa UK Ltd - Curr Med Res Opin 2009; 25(8)”
BackgroundInfluentialHoffmann, I., Kohl, M., von Stengel, S., Jakob, F., Kerschan-Schindl, K., Lange, U., Peters, S., Schoene, D., Sieber, C., Thomasius, F., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06592-8 · Cited by 49
Shahnazari, M., Yao, W., Dai, W., Wang, B., Ionova-Martin, S. S., Ritchie, R. O., Heeren, D., Burghardt, A. J., Nicolella, D. P., Kimiecik, M. G., et al. (2010) · Bone · doi:10.1016/j.bone.2009.11.019 · Cited by 46
“…ibandronate (Ibn) and risedronate (Ris) in aged ovariectomized (OVX) rats treated with doses comparable to, or higher than, the clinical doses prescribed for the treatment and prevention of postmenopausal osteoporosis and used by Delmas et al. [22] [23], Black et al. [10], and Lewiecki et al. [11].”
Osteoporosis after spinal cord injury: aetiology, effects and therapeutic approaches.
Abdelrahman, S., Ireland, A., Winter, E. M., Purcell, M., & Coupaud, S. (2021) · PubMed Central · Cited by 66
VARENNA, M., Bertoldo, F., Monaco, M., Giusti, A., Martini, G., Rossini, M., SIOMMMS, O. B. O., & Endorsed by, S. I. R. (2013) · Reumatismo · doi:10.4081/reumatismo.2013.143 · Cited by 54
Current and future treatment options in osteoporosis
Brewer, L., Williams, D. J., & Moore, A. R. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-0999-2 · Cited by 49
“Annual ZA reduces vertebral and hip fracture by 70% and 41% respectively compared with placebo [ 28 ] and offers 35% relative reduction in recurrent fracture and all-cause mortality (HR 0.72) when given 2 weeks after hip fracture [29, 30].”
BackgroundInfluentialEffects of antiresorptive treatment on nonvertebral fracture outcomes
Mackey, D. C., Black, D. M., Bauer, D. C., McCloskey, E. V., Eastell, R., Mesenbrink, P. G., Thompson, J. R., & Cummings, S. R. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.446 · Cited by 48
“…Trt: 1817 Clodronate McCloskey et al., 2007(15) Age 75, unselected for osteoporosis 800mg PO daily for 3 years Plb: 2606 Trt: 2606 Zoledronic acid Black et al., 2007(2) Age 65–89, femoral neck BMD T-score 2.5 or femoral neck BMD T-score 1.5 with at least two mild or one moderate radiologic…”
BackgroundMethodSelf-citationRenal safety of intravenous bisphosphonates in the treatment of osteoporosis
Lewiecki, E. M., & Miller, P. D. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.663 · Cited by 46
Dempster, D. W., Roschger, P., Misof, B. M., Zhou, H., Paschalis, E. P., Alam, J., Ruff, V. A., Klaus Klaushofer, A., & Taylor, K. A. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2825 · Cited by 46
“These distinct and different effects of TPTD and ZOL on the skeleton are thought to contribute to the beneficial effect on fracture risk reduction.((28,29))”
BackgroundBisphosphonates pharmacology and use in the treatment of osteoporosis
Diab, D. L., Watts, N. B., & Miller, P. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00074-5 · Cited by 48
Serrano, A. J., Begoña, L., Anitua, E., Campos, R. C., & Orive, G. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2013.813468 · Cited by 53
“This heterogeneity appears to be due to the study ‘‘Horizon Recurrent 2007’’ [19].”
ResultUse of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis
Rhee, C. W., Lee, J.-S., Oh, S., Choi, N., & Park, B. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1608-z · Cited by 44
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
Saag, K. G., & Geusens, P. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2815 · Cited by 50
Pulkkinen, P., Glüer, C., & Jämsä, T. J. (2011) · Bone · doi:10.1016/j.bone.2011.07.022 · Cited by 47
“Given the much weaker fracture reduction effect for hip fracture (around 40%) when compared to vertebral fractures (around 70%) [80,81] a need for further improvement is obvious.”
BackgroundUse of bisphosphonates in the management of postmenopausal osteoporosis
Papapoulos, S. E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05767.x · Cited by 48
Ruggiero, C., Baroni, M., Xenos, D., Parretti, L., Macchione, I. G., Bubba, V., Laudisio, A., Pedone, C., Ferracci, M., Magierski, R., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102130 · Cited by 54
“These changes were similar to those in healthy, younger women (Black et al., 2007), with no significant differences in serious adverse events through 24 months.”
Osteoporosis Diagnosis and Medical Treatment
Warriner, A. H., & Saag, K. G. (2013) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2013.01.005 · Cited by 53
Hollick, R. J., & Reid, D. M. (2011) · Menopause international · doi:10.1258/mi.2011.011014 · Cited by 46
Doi, Y., Miyazaki, M., Yoshiiwa, T., Hara, K., Kataoka, M., & Tsumura, H. (2011) · Bone · doi:10.1016/j.bone.2011.07.005 · Cited by 44
“Bisphosphonates have improved the clinical outcomes of osteoporosis, Paget's disease, and metastatic bone disease in [12–14].”
BackgroundOsteoporosis treatment and atrial fibrillation
Huang, W.-F., Tsai, Y., Wen, Y., Hsiao, F., Kuo, K. N., & Tsai, C.-R. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181b34749 · Cited by 43
“Only recently, based on reports from the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly trial, have concerns over the use of these drugs and risk of AF been raised.(16) This association was supported by results of the Fracture Intervention Trial(18) and those of a large population-based case-co…”
BackgroundResultInfluentialChen, B., Li, Y., Yang, X., Xu, H., & Xie, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2288-7 · Cited by 45
“Clinical studies have showed pronounced efficacy of yearly 5-mg infusions of zoledronic acid in improving osteoporosis and decreasing hip, vertebral, and nonvertebral fractures [19, 20].”
BackgroundEffects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism
Ochi, Y., Yamada, H., Mori, H., Nakanishi, Y., Nishikawa, S., Kayasuga, R., Kawada, N., Kunishige, A., Hashimoto, Y., Tanaka, M., et al. (2011) · Bone · doi:10.1016/j.bone.2011.09.041 · Cited by 48
“While bisphosphonates have been shown to reduce the risk for vertebral fractures by 40% to 70%, their reduction of the risk for non-vertebral fractures is as low as 20% to 40% [2–5].”
BackgroundIntravenous zoledronate improves bone density in adults with cystic fibrosis (CF)
Chapman, I., Greville, H. W., Ebeling, P. R., King, S., Kotsimbos, T. C., Nugent, P., Player, R., Topliss, D. J., Warner, J., & Wilson, J. W. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03434.x · Cited by 43
Fracture incidence after 3 years of aromatase inhibitor therapy
Bouvard, B., Soulié, P., Hoppé, E., Georgin-Mège, M., Royer, M., Mesgouez‐Nebout, N., Lassalle, C., Cellier, P., Jadaud, E., Abadie‐Lacourtoisie, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu008 · Cited by 45
“Intravenous bisphosphonate could be a good means to avoid the problem of adherence, it has been shown to reduce vertebral and hip fracture risk in frail patients [19] and its efficacy in the 1.”
BackgroundEffect of zoledronic acid on lumbar spinal fusion in osteoporotic patients
Ding, Q., Chen, J., Fan, J., Li, Q., Yin, G., & Yu, L. (2017) · European Spine Journal · doi:10.1007/s00586-017-5286-1 · Cited by 44
Diagnosis and Management of Osteoporosis
Lash, R. W., Nicholson, J. M., Vélez, L., Harrison, R. V., & McCort, J. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.10.009 · Cited by 51
Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments
Inderjeeth, C. A., Chan, K., Kwan, K., & Lai, M. M. Y. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0349-1 · Cited by 49
Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months
Bolland, M. J., Grey, A. B., Horne, A. M., Briggs, S. E., Thomas, M. G., Ellis-Pegler, R. B., Callon, K. E., Gamble, G. D., & Reid, I. R. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080312 · Cited by 45
“When administered annually for 3 yr to osteoporotic postmenopausal women by intravenous infusion, zoledronate reduced vertebral fractures by 70%, hip fractures by 41%, and total nonvertebral fractures by 25%,((1)) and similar beneficial effects have been reported in those treated after hip fractures.”
BackgroundResultSelf-citationBillington, E. O., Aghajafari, F., Skulsky, E., & Kline, G. A. (2024) · BMJ · doi:10.1136/bmj-2023-076898 · Cited by 51
Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease
Sbrocchi, A. M., Forget, S., Laforte, D., Azouz, E. M., & Rodd, C. J. (2010) · Pediatrics International · doi:10.1111/j.1442-200x.2010.03174.x · Cited by 43
Gamsjaeger, S., Hofstetter, B., Zwettler, E., Recker, R. R., Gasser, J. A., Eriksen, E. F., Klaushofer, K., & Paschalis, E. P. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2202-8 · Cited by 43
Self-citationUndertreatment of osteoporosis following hip fracture in the elderly
Lüthje, P. M. J., Nurmi-Lüthje, I., Kaukonen, J.-P., Kuurne, S., Naboulsi, H., & Kataja, M. (2008) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2008.06.007 · Cited by 43
“One further alternative could be the use of intravenous administration of zoledronic acid once a year, which ensures that patients will have a full treatment effect for at least 12 months (Black et al., 2007).”
BackgroundBisphosphonate Remains Highly Localized After Elution From Porous Implants
McKenzie, K., Bobyn, D. J., Roberts, J., Karabasz, D., & Tänzer, M. (2010) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-010-1527-x · Cited by 43
“and zoledronic acid [5, 7, 20, 21, 25–27], the most potent and long-lasting bisphosphonate and one of several thirdgeneration compounds being used clinically to mitigate the effects of osteoporosis [4, 16].”
BackgroundWhat’s in a name? What constitutes the clinical diagnosis of osteoporosis?
Siris, E. S., Boonen, S., Mitchell, P., Bilezikian, J. P., & Silverman, S. L. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1991-0 · Cited by 48
Self-citationNurmi-Lüthje, I., Lüthje, P. M. J., Kaukonen, J.-P., Kataja, M., Kuurne, S., Naboulsi, H., & Karjalainen, K. (2009) · Drugs & Aging · doi:10.2165/00002512-200926050-00005 · Cited by 42
Vohra, F. A., Al-Rifaiy, M. Q., Almas, K., & Javed, F. (2014) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2014.05.016 · Cited by 43
Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures.
Corrado, A., Neve, A., Maruotti, N., Gaudio, A., Marucci, A., & Cantatore, F. P. (2010) · PubMed · Cited by 43
Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use
Lyu, H., Zhao, S. S., Yoshida, K., Tedeschi, S. K., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00924 · Cited by 43
Update on the treatment of post-menopausal osteoporosis
Cole, Z. A., Dennison, E. M., & Cooper, C. C. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn017 · Cited by 44
Pazianas, M., Clark, E., Eiken, P., Brixen, K., & Abrahamsen, B. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1783 · Cited by 43
Charcot foot and ankle with osteomyelitis
Donegan, R. J., Sumpio, B. E., & Blume, P. A. (2013) · Diabetic Foot & Ankle · doi:10.3402/dfa.v4i0.21361 · Cited by 47
“(66) studied the use of bisphosphonates for postmenopausal osteoporosis and reported that serious atrial fibrillation occurred more frequently in the bisphosphonate group than in the placebo-controlled group.”
BackgroundSiddique, M. M., Frost, M. L., Blake, G. M., Moore, A. E. B., Al-Beyatti, Y., Marsden, P. K., Schleyer, P. J., & Fogelman, I. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.093195 · Cited by 43
Kim, J. E., Ahn, J., Jung, K. H., Kim, S., Kim, H. J., Lee, K.-S., Ro, J., Park, Y., Ahn, J.-S., Im, Y.-H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1201-8 · Cited by 42
“Although the appropriate dose and duration of ZA have not yet been determined, once-yearly infusion of ZA was found to significantly improve loss of BMD in postmenopausal women with osteoporosis [20, 21].”
BackgroundRole of zoledronic acid in the prevention and treatment of osteoporosis
Ste‐Marie, L., Rakel, A., Boucher, A., & Ste‐Marie, L. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s7282 · Cited by 52
“Efficacy Postmenopausal women The efficacy of Zol was demonstrated in HORIZON-PFT for the treatment of osteoporosis in postmenopausal women.(25) C lin ic al In te rv en tio ns in A gi ng d ow nl oa de d fr om h ttp s: //w w w .”
InfluentialThe Unrecognized Burden of Osteoporosis-Related Vertebral Fractures in Patients With Heart Failure
Lyons, K. J., Majumdar, S. R., & Ezekowitz, J. A. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.961185 · Cited by 44
New Approaches to the Treatment of Osteoporosis
Silva, B. C. C., & Bilezikian, J. P. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-061709-145401 · Cited by 42
Osteoporosis and Its Implications for Dental Patients
Edwards, B. J.-A., & Migliorati, C. A. (2008) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2008.0214 · Cited by 43
Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F. A. F., Bonadonna, S., Camozzi, V., Cassibba, S., Cesareo, R., Chiodini, I., Francucci, C. M., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0434-8 · Cited by 45
Importance of Recent Fracture as Predictor of Imminent Fracture Risk
Schnell, A., Curtis, J. R., & Saag, K. G. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0487-z · Cited by 46
Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults
Zullo, A. R., Zhang, T., Lee, Y., McConeghy, K. W., Daiello, L. A., Kiel, D. P., Mor, V., & Berry, S. D. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15725 · Cited by 43
“Prior trials suggest that bisphosphonates may start to reduce fracture risk as early as 6 months after treatment initiation.(44) Our study found a similar lag time to benefit for hip fracture.”
BackgroundEnsrud, K. E., Kats, A. M., Boyd, C. M., Diem, S. J., Schousboe, J. T., Taylor, B. C., Bauer, D. C., Stone, K. L., & Langsetmo, L. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0682 · Cited by 47
Medical treatment of osteoporosis
Palacios, S. (2021) · Climacteric · doi:10.1080/13697137.2021.1951697 · Cited by 51
Iwamoto, J. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s3177 · Cited by 41
“…drugs, however, only alendronate, risedronate, intravenous zoledronate, strontium ranelate, and hormone replacement therapy (HRT) have shown anti-fracture effi cacy against hip fractures in post-menopausal women (Black et al 1996, 2007; McClung et al 2001; Rossouw et al 2002; Reginster et al 2005).”
The role of zoledronic acid in the management of osteoporosis
Maricic, M. J. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1486-3 · Cited by 43
Bone mineral loss at the proximal femur in acute spinal cord injury
Edwards, W. B., Schnitzer, T. J., & Troy, K. L. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2323-8 · Cited by 45
Adverse bone effects during pharmacological breast cancer therapy
Bjarnason, N. H., Hitz, M. F., Jørgensen, N. R., Vestergaard, P., & (on behalf of the board of Danish Bone Society) (2008) · Acta Oncologica · doi:10.1080/02841860802001467 · Cited by 45
Wimalawansa, S. J. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.4.491 · Cited by 50
“However, there is no data supporting the usefulness of this recommendation [19,88] .”
BackgroundEfficacy of Infliximab in Cogan’s Syndrome
Ghadban, R., Couret, M., & Zénone, T. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080203 · Cited by 42
Popp, A. W., Senn, R., Curkovic, I., Senn, C., Buffat, H., Popp, P. F., & Lippuner, K. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3992-5 · Cited by 44
Misof, B. M., Bodingbauer, M., Roschger, P., Wekerle, T., Pakrah, B., Haas, M., Kainz, A., Oberbauer, R., Mühlbacher, F., & Klaushofer, K. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9161-2 · Cited by 41
“However, beneficial effects of high-dose ZOL on fracture rates, mortality, as well as BMD have been found in our patients [16] and at much lower ZOL doses for postmenopausal women [43, 44 ].”
BackgroundOcular Side Effects of Bisphosphonates: A Review of Literature
Chartrand, N., Lau, C.-K., Parsons, M. T., Handlon, J. J., Ronquillo, Y. C., Hoopes, P. C., & Moshirfar, M. (2022) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0094 · Cited by 52
Prevention and Clinical Management of Hip Fractures in Patients With Dementia
Menzies, I. B., Mendelson, D. A., Kates, S. L., & Friedman, S. M. (2010) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458510389465 · Cited by 46
New Treatment Modalities in Osteoporosis
CANALIS, E. M. (2010) · Endocrine Practice · doi:10.4158/ep10048.ra · Cited by 45
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.